Biosign Introduces Ambulatory Blood Pressure Monitor

    
    /THIS PRESS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR
    FOR DISSEMINATION IN THE UNITED STATES/
    

TORONTO, Sept. 25 /CNW/ - Biosign Technologies Inc. (CNSX: BIO), a leading developer of biomedical systems, announced today the introduction of its UFIT(R) system to the ambulatory blood pressure monitoring market.

Ambulatory Blood Pressure Monitoring (ABPM) involves collecting multiple blood pressure readings in real life situations over a period of time. There are clear medical benefits to ABPM as compared to blood pressure taken at medical offices or drugstores. Overall, ABPM is thought to enhance the evaluation and management of major cardiovascular risks, such as high blood pressure (hypertension).

The market for ABPM is large and growing. There are currently over one billion people living with hypertension worldwide, a number expected to escalate to more than 1.56 billion by the year 2025. The demand, however, is hardly satisfied as ABPM is fraught with technical problems. A solution to these problems could unlock an annual market of about $6 billion in North America(1).

Biosign addresses the opportunity by introducing its online blood pressure monitor (UFIT(R) TEN-10) to the ABPM market. Operating without startling, discomforting, or otherwise stressing the patient, the monitor can be set locally or remotely to gather data regularly, randomly, or intelligently by automatically adjusting the intervals between measurements and the length of monitoring according to clinical guidelines and aims. This minimizes the generation of redundant and confusing data, reducing the time, cost, and inconvenience of ABPM.

As the same device may be used for office, ambulatory and self-monitoring purposes, the monitor can serve as a 'virtual blood pressure clinic'. Electronic linkages between the patient and provider enable continuity of care, as the monitor switches between ABPM and self-monitoring modes, as needed for diagnosis, follow-up, or maintenance.

UFIT(R) for ABPM will be available to clinical practices in Canada this month.

    
    ------------------------------
    1  Appel, L. J. and W. B. Stason "Ambulatory Blood Pressure Monitoring
       and Blood Pressure Self-Measurement in the Diagnosis and Management of
       Hypertension." Ann Intern Med 118 (11): 867-882
    

About Biosign Technologies Inc.

Biosign provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, and medication. The core technology combines universal measurement, remote monitoring, and rapid knowledge formation to support health care across global markets. The UFIT(R) technology powers quality data collection and analytics for clinical diagnostics, disease evaluation & management, remote patient monitoring, and self-care. For more information on Biosign please visit http://www.biosign.com.

Forward-Looking Statements

This press release contains forward looking statements. Forward looking statements are not based on historical facts, but rather on current expectations, Company assumptions and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward looking statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Company assumptions and risk factors are listed from time to time in Biosign's reports, public disclosure documents including Management's Discussion and Analysis, Management Information Circular, and in other filings with stock exchanges and securities regulatory authorities in Canada.

You should not place undue importance on forward-looking statements and should not rely upon this information as of any other date. While Biosign may elect to, Biosign is under no obligation and does not undertake to update this information at any particular time. This press release was prepared by management from information available to the date of this release.

    
    The CNSX has neither approved nor disapproved the contents of this press
    release.
    

%SEDAR: 00014068E

SOURCE Biosign Technologies Inc.

For further information: For further information: Radu Leca, President & CEO, Biosign Technologies Inc., Phone: (416) 218-9800 ext. 234, Email: ceo@biosign.com

Organization Profile

Biosign Technologies Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890